Dermisonics Net Income From Continuing Ops from 2010 to 2026
Dermisonics' Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is predicted to flatten to about -4.8 M. For the period between 2010 and 2026, Dermisonics, Net Loss quarterly trend regression had median of (5,084,047) and r-value of (0.35). View All Fundamentals
Check out the analysis of Dermisonics Correlation against competitors. For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.
Net Loss | First Reported 2010-12-31 | Previous Quarter -4.6 M | Current Value -4.8 M | Quarterly Volatility 1.2 M |
Check Dermisonics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermisonics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 3.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.04. Dermisonics financial statements analysis is a perfect complement when working with Dermisonics Valuation or Volatility modules.
Dermisonics | Net Income From Continuing Ops | Build AI portfolio with Dermisonics Stock |
The Net Income From Continuing Ops trend for Dermisonics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Dermisonics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Dermisonics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Dermisonics over the last few years. It is Dermisonics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermisonics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Dermisonics Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (4,741,889) | |
| Coefficient Of Variation | (25.63) | |
| Mean Deviation | 570,911 | |
| Median | (5,084,047) | |
| Standard Deviation | 1,215,365 | |
| Sample Variance | 1.5T | |
| Range | 5M | |
| R-Value | (0.35) | |
| Mean Square Error | 1.4T | |
| R-Squared | 0.12 | |
| Significance | 0.17 | |
| Slope | (84,396) | |
| Total Sum of Squares | 23.6T |
Dermisonics Net Income From Continuing Ops History
About Dermisonics Financial Statements
Investors use fundamental indicators, such as Dermisonics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Dermisonics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.6 M | -4.8 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Dermisonics Correlation against competitors. For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is there potential for Medical Devices market expansion? Will Dermisonics introduce new products? Factors like these will boost the valuation of Dermisonics. Projected growth potential of Dermisonics fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dermisonics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Dermisonics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Dermisonics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Dermisonics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Dermisonics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermisonics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Dermisonics' market price signifies the transaction level at which participants voluntarily complete trades.